USP Elemental Impurities Implementation Set for January 2018
USP establishes Jan. 1, 2018 as the implementation date for its elemental impurities guidelines for existing drugs.
The US Pharmacopeial Convention (USP) has announced plans to establish Jan. 1, 2018 as the new date of applicability of General Chapters <232> Elemental Impurities-Limits and <2232> Elemental Contaminants in Dietary Supplements. The date change was made to align more closely with implementation of the International Conference on Harmonization (ICH) Q3D, Guideline for Elemental Impurities.
In December 2014, ICH released the Step 4 version of ICH Q3D, Guidelines for Elemental Impurities, to regional standards organizations for implementation. The document stated that application of ICH Q3D to existing products was not expected prior to 36 months after publication.
USP reports that that users can continue to use the current General Chapter <231> Heavy Metals approach or implement the new <232>/<2232> approaches until Jan. 1, 2018, at which time General Chapters <232> and <2232> will be made applicable to drug product and dietary supplement monographs as described in General Notices 5.60.30.
Source: US Pharmacopeial Convention
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
